Effect of zonisamide on serum immunoglobulins.
Zonisamide (AD-810) was additionally administered to 19 patients with refractory epilepsy who had been receiving multiple antiepileptic drugs and the effect of zonisamide on serum immunoglobulins was investigated. Zonisamide was administered in daily dose of 200-700 mg (mean 389 mg) for the period of 82-1,470 days (mean 863 days). The serum levels of IgG, IgA and IgM were determined before administration and at intervals of 3 or 6 months over the period of a maximum of 48 months after initiation of administration. There was no significant change in immunoglobulin levels at any time after initiation of zonisamide treatment as compared with the pretreatment levels. No significant correlation was found between the dose or serum concentration of zonisamide and the immunoglobulin levels.
Fujimoto
Y
Y
Department of Psychiatry, Nissei Hospital, Osaka, Japan.
Ikoma
R
R
Shimizu
T
T
Shimizu
A
A
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D004827:Epilepsy / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000032:analysis; D007075:Immunoglobulin M / Q000032:analysis; D007136:Immunoglobulins / Q000032:analysis*; D007555:Isoxazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D000078305:Zonisamide
D000927:Anticonvulsants; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007136:Immunoglobulins; D007555:Isoxazoles; D000078305:Zonisamide